Signl
Signl develops small-molecule adjuvants that decouple vaccine-induced inflammation from protective immune response, allowing higher efficacy without increasing reactogenicity. The compounds act on central nodes of innate immune signaling rather than receptor binding, and co-formulate with existing vaccine platforms including mRNA, subunit, inactivated, and polysaccharide formats across delivery systems such as lipid nanoparticles, liposomes, and oil-in-water emulsions.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
For thirty years, vaccine development has relied on a single lever: turning up the immune response also increases inflammation, keeping the two coupled. This forces dose caps based on patient tolerability rather than on the level of protection achievable, limiting vaccine efficacy and shaping entire development programs around reactogenicity constraints.
Solution
Signl develops small-molecule adjuvants that decouple vaccine-induced inflammation from protective immune response by acting on central nodes of innate immune signaling rather than on receptor binding. This allows the inflammatory arm and protective arm of an immune response to be set independently, enabling higher efficacy without increasing side effects. The molecules co-formulate with existing vaccine platforms—including mRNA, subunit, inactivated, and polysaccharide formats—and work across common delivery systems such as lipid nanoparticles, liposomes, and oil-in-water emulsions. This means Signl's technology can be integrated into vaccine programs already in development without requiring new delivery infrastructure.
Target Audience
Primary customers are vaccine developers and pharmaceutical companies working across mRNA, subunit, inactivated, and polysaccharide platforms who need to improve efficacy without increasing reactogenicity.
Features
- Small-molecule adjuvants targeting central nodes of innate immune signaling rather than receptor binding
- Decouples inflammatory response from protective immune response, allowing independent tuning of each
- Co-formulates with mRNA, subunit, inactivated, and polysaccharide vaccine types
- Compatible with lipid nanoparticle, liposome, and oil-in-water emulsion delivery systems
- Designed to integrate into existing vaccine platforms and manufacturing workflows